Table 3.
Comparison of patient data between 2006 and 2016
| 2006 | 2016 | P | |
|---|---|---|---|
| Total patients | 114 | 125 | |
| Mean age (years±SD) | 62.1±8.22 | 66.94±9.123 | <0.001 |
| Serum PSA (ng/ml) | 4.391±4.425 | 5.590±7.61 | 0.1427 |
| Prior medical therapy, n (%) | 71 (62.2) | 94 (75.2) | 0.0359 |
| CCI, n (%) | |||
| 0 | 88 (77.2) | 80 (64.0) | 0.0333 |
| 1 | 20 (17.5) | 37 (29.6) | 0.0336 |
| ≥2 | 6 (5.3) | 8 (6.4) | 0.7875 |
| Mean prostatic volume (g±SD) | 52.6±18.34 | 57.974±21.79 | 0.0412 |
| Indication for surgery, n (%) | |||
| Moderate to severe LUTS | 32 (28.1) | 39 (31.2) | - |
| Recurrent urinary retention | 56 (49.1) | 63 (50.4) | |
| Recurrent urinary tract infection | 8 (7.1) | 7 (5.6) | |
| Recurrent hematuria | 4 (3.5) | 3 (2.4) | |
| Bladder calculus | 9 (7.9) | 7 (5.6) | |
| Others | 5 (4.4) | 6 (4.8) | |
| Operative time (min±SD) | 63.2±26.45 | 62.6±34.72 | 0.8815 |
| Weight of prostatic chips (g±SD) | 22.4±13.8 | 26.8±16.7 | 0.0282 |
| Mean duration of hospitalization (days±SD) | 2.56±1.02 | 2.51±1.36 | 0.7499 |
SD: Standard deviation, PSA: Prostate-specific antigen, LUTS: Lower urinary tract symptoms, CCI: Charlson comorbidity index